These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15555886)

  • 21. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
    Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.
    Frean JA; Arntzen L; Capper T; Bryskier A; Klugman KP
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2646-7. PubMed ID: 8913481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimicrobial agents.
    Hernandez E; Girardet M; Ramisse F; Vidal D; Cavallo JD
    J Antimicrob Chemother; 2003 Dec; 52(6):1029-31. PubMed ID: 14613959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.
    Leary SE; Griffin KF; Galyov EE; Hewer J; Williamson ED; Holmström A; Forsberg A; Titball RW
    Microb Pathog; 1999 Mar; 26(3):159-69. PubMed ID: 10089156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
    Atkins HS; Spencer S; Brew SD; Laws TR; Thirlwall RE; MacMillan AP; Brooks TJ; Simpson AJ
    Int J Antimicrob Agents; 2009 Nov; 34(5):471-3. PubMed ID: 19682862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standardized Method for Aerosol Challenge of Rodents with Yersinia pestis for Modeling Primary Pneumonic Plague.
    Anderson PE; Olson RM; Willix JL; Anderson DM
    Methods Mol Biol; 2019; 2010():29-39. PubMed ID: 31177429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibiotics of the aminoglycoside group (gentamicin, sisomicin and amikacin) in the prevention and treatment of experimental plague].
    Shcherbaniuk AI; Makarovskaia LN; Bugaeva OK; Kasatkina IV
    Antibiot Khimioter; 1992 May; 37(5):30-1. PubMed ID: 1417325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
    Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
    Feodorova VA; Pan'kina LN; Savostina EP; Sayapina LV; Motin VL; Dentovskaya SV; Shaikhutdinova RZ; Ivanov SA; Lindner B; Kondakova AN; Bystrova OV; Kocharova NA; Senchenkova SN; Holst O; Pier GB; Knirel YA; Anisimov AP
    Vaccine; 2007 Nov; 25(44):7620-8. PubMed ID: 17913308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
    Bonacorsi SP; Scavizzi MR; Guiyoule A; Amouroux JH; Carniel E
    Antimicrob Agents Chemother; 1994 Mar; 38(3):481-6. PubMed ID: 8203841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
    Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
    Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of rifampicin in experimental plague infection].
    Makarovskaia LN; Shcherbaniuk AI; Bugaeva OK
    Antibiot Khimioter; 1993 Jul; 38(7):34-6. PubMed ID: 8161275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
    Louie A; Deziel MR; Liu W; Drusano GL
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2661-7. PubMed ID: 17517837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
    Hewitt JA; Lanning LL; Campbell JL
    Clin Infect Dis; 2020 May; 70(70 Suppl 1):S51-S59. PubMed ID: 32435803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic Therapy of Plague: A Review.
    Sebbane F; Lemaître N
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cefoperazone in the prevention and treatment of experimental plague caused by typical and fraction-free pathogen strains in white mice].
    Pasiukov VV; Ryzhko IV; Tsuraeva RI; Samokhodkina ED; Roshchina NV
    Antibiot Khimioter; 1994 Aug; 39(8):37-40. PubMed ID: 7695439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional profiling of a mice plague model: insights into interaction between Yersinia pestis and its host.
    Liu H; Wang H; Qiu J; Wang X; Guo Z; Qiu Y; Zhou D; Han Y; Du Z; Li C; Song Y; Yang R
    J Basic Microbiol; 2009 Feb; 49(1):92-9. PubMed ID: 18759226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antimicrobial susceptibilities of strains of Yersinia pestis.
    Smith MD; Vinh DX; Nguyen TT; Wain J; Thung D; White NJ
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2153-4. PubMed ID: 8540736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ceftriaxone in prevention and treatment of experimental plague infection].
    Ryzhko IV; Samokhodkina ED; Zhigalova TA
    Antibiot Khimioter; 1993 Jan; 38(1):39-42. PubMed ID: 8060183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.